| David Allen Faris, MD | |
|
1219 Johnson Ave, Suite 103, Bridgeport, WV 26330-1353 | |
| (304) 842-8888 | |
| (304) 842-7629 |
| Full Name | David Allen Faris |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 40 Years |
| Location | 1219 Johnson Ave, Bridgeport, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811056252 | NPI | - | NPPES |
| 0095290000 | Medicaid | WV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | WV16046 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| United Hospital Center | Bridgeport, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| United Hospital Center Inc | 8123936010 | 209 |
News Archive
Holidays abroad may hold the key to tackling Scotland's vitamin D deficiency, research suggests.
The aetiology and clinical features of community-acquired pneumonia are different in people with chronic obstructive pulmonary disease than in those without the lung condition, Spanish research demonstrates.
Ten years after the Iraq war of 2003 a team of scientists based in Mosul, northern Iraq, have detected high levels of uranium contamination in soil samples at three sites in the province of Nineveh which, coupled with dramatically increasing rates of childhood cancers and birth defects at local hospitals, highlight the ongoing legacy of modern warfare to civilians in conflict zones.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).
In new research appearing in the prestigious journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. This groundbreaking development could help advance a variety of liver-related research and applications, from studying drug toxicity to creating bio-artificial liver support for patients awaiting transplantations.
› Verified 4 days ago
| Entity Name | United Hospital Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760965586 PECOS PAC ID: 8123936010 Enrollment ID: O20031212000802 |
News Archive
Holidays abroad may hold the key to tackling Scotland's vitamin D deficiency, research suggests.
The aetiology and clinical features of community-acquired pneumonia are different in people with chronic obstructive pulmonary disease than in those without the lung condition, Spanish research demonstrates.
Ten years after the Iraq war of 2003 a team of scientists based in Mosul, northern Iraq, have detected high levels of uranium contamination in soil samples at three sites in the province of Nineveh which, coupled with dramatically increasing rates of childhood cancers and birth defects at local hospitals, highlight the ongoing legacy of modern warfare to civilians in conflict zones.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).
In new research appearing in the prestigious journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. This groundbreaking development could help advance a variety of liver-related research and applications, from studying drug toxicity to creating bio-artificial liver support for patients awaiting transplantations.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Allen Faris, MD 1219 Johnson Ave, Ste 103, Bridgeport, WV 26330-1353 Ph: (304) 842-8888 | David Allen Faris, MD 1219 Johnson Ave, Suite 103, Bridgeport, WV 26330-1353 Ph: (304) 842-8888 |
News Archive
Holidays abroad may hold the key to tackling Scotland's vitamin D deficiency, research suggests.
The aetiology and clinical features of community-acquired pneumonia are different in people with chronic obstructive pulmonary disease than in those without the lung condition, Spanish research demonstrates.
Ten years after the Iraq war of 2003 a team of scientists based in Mosul, northern Iraq, have detected high levels of uranium contamination in soil samples at three sites in the province of Nineveh which, coupled with dramatically increasing rates of childhood cancers and birth defects at local hospitals, highlight the ongoing legacy of modern warfare to civilians in conflict zones.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).
In new research appearing in the prestigious journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. This groundbreaking development could help advance a variety of liver-related research and applications, from studying drug toxicity to creating bio-artificial liver support for patients awaiting transplantations.
› Verified 4 days ago
Dr. George Condax, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 527 Medical Park Dr, Suite 106, Bridgeport, WV 26330 Phone: 304-933-3860 Fax: 304-933-3861 |